Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.
Marvaso G, Isaksson LJ, Zaffaroni M, Vincini MG, Summers PE, Pepa M, Corrao G, Mazzola GC, Rotondi M, Mastroleo F, Raimondi S, Alessi S, Pricolo P, Luzzago S, Mistretta FA, Ferro M, Cattani F, Ceci F, Musi G, De Cobelli O, Cremonesi M, Gandini S, La Torre D, Orecchia R, Petralia G, Jereczek-Fossa BA. Marvaso G, et al. Among authors: ceci f. Eur Radiol. 2024 Mar 20. doi: 10.1007/s00330-024-10699-3. Online ahead of print. Eur Radiol. 2024. PMID: 38507053
Hypofractionated proton therapy for benign tumors of the central nervous system: A systematic review of the literature.
Piperno G, Ferrari A, Volpe S, Cattani F, Zaffaroni M, Comi S, Pansini F, Bergamaschi L, Mazzola GC, Ceci F, Colandrea M, Petralia G, Orecchia R, Jereczek-Fossa BA, Alterio D. Piperno G, et al. Among authors: ceci f. Crit Rev Oncol Hematol. 2023 Nov;191:104114. doi: 10.1016/j.critrevonc.2023.104114. Epub 2023 Sep 6. Crit Rev Oncol Hematol. 2023. PMID: 37683814 Review.
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.
Volpe S, Zaffaroni M, Piperno G, Vincini MG, Zerella MA, Mastroleo F, Cattani F, Fodor CI, Bellerba F, Bonaldi T, Bonizzi G, Ceci F, Cremonesi M, Fusco N, Gandini S, Garibaldi C, Torre D, Noberini R, Petralia G, Spaggiari L, Venetis K, Orecchia R, Casiraghi M, Jereczek-Fossa BA. Volpe S, et al. Among authors: ceci f. BMC Cancer. 2023 Dec 15;23(1):1236. doi: 10.1186/s12885-023-11701-9. BMC Cancer. 2023. PMID: 38102575 Free PMC article.
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.
Collamati F, Morganti S, van Oosterom MN, Campana L, Ceci F, Luzzago S, Mancini-Terracciano C, Mirabelli R, Musi G, Nicolanti F, Orsi I, van Leeuwen FWB, Faccini R. Collamati F, et al. Among authors: ceci f. Eur J Nucl Med Mol Imaging. 2024 Feb 20. doi: 10.1007/s00259-024-06653-6. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376805
Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G, Corrao G, Repetti I, Lorubbio C, Bellerba F, Zaffaroni M, Vincini MG, Zerini D, Alessi S, Luzzago S, Mistretta FA, Fodor C, Cambria R, Cattani F, Ceci F, Musi G, De Cobelli O, Zilli T, Gandini S, Orecchia R, Petralia G, Jereczek-Fossa BA. Marvaso G, et al. Among authors: ceci f. World J Urol. 2024 Mar 16;42(1):169. doi: 10.1007/s00345-024-04876-8. World J Urol. 2024. PMID: 38492078
Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis.
Corrao G, Marvaso G, Mastroleo F, Biffi A, Pellegrini G, Minari S, Vincini MG, Zaffaroni M, Zerini D, Volpe S, Gaito S, Mazzola GC, Bergamaschi L, Cattani F, Petralia G, Musi G, Ceci F, De Cobelli O, Orecchia R, Alterio D, Jereczek-Fossa BA. Corrao G, et al. Among authors: ceci f. Radiother Oncol. 2024 Jun;195:110264. doi: 10.1016/j.radonc.2024.110264. Epub 2024 Mar 30. Radiother Oncol. 2024. PMID: 38561122 Review.
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Djaïleb L, et al. Among authors: ceci f. Eur Urol. 2023 Dec;84(6):588-596. doi: 10.1016/j.eururo.2023.06.022. Epub 2023 Jul 21. Eur Urol. 2023. PMID: 37482512 Clinical Trial.
Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, Cisero E, Semko S, Checcucci E, Devos G, Apfelbeck M, Gatti C, Marra G, van den Bergh RCN, Goldner G, Rasul S, Ceci F, Dal Moro F, Porpiglia F, Gontero P, Bjartell A, Stief C, Heidenreich A, Joniau S, Briganti A, Shariat SF, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Rajwa P, et al. Among authors: ceci f. Eur Urol Oncol. 2023 Oct 14:S2588-9311(23)00197-9. doi: 10.1016/j.euo.2023.09.006. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37845121 Free article.
264 results